Preconditioning of mesenchymal stem cells for improved transplantation efficacy in recessive dystrophic epidermolysis bullosa

Stem Cell Research and Therapy

Volumn 5, Issue 6, 2014, Pages

  Perdoni, Christopher ^a   McGrath, John A ^b   Tolar, Jakub ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; COLLAGEN TYPE 7; STROMAL CELL DERIVED FACTOR 1ALPHA; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; COL7A1 PROTEIN, HUMAN; STROMAL CELL DERIVED FACTOR 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ISOLATION; COL7A1 GENE; CONTROLLED STUDY; CXCR4 GENE; EPIDERMOLYSIS BULLOSA DYSTROPHICA; EXPERIMENTATION; GENE; GENE EXPRESSION; IN VITRO STUDY; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; MOUSE; NONHUMAN; PRECONDITIONING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; RECESSIVE EPIDERMOLYSIS BULLOSA DYSTROPHICA; TSG 6 GENE; UPREGULATION; ANIMAL; CELL CULTURE; DRUG EFFECTS; GENETICS; MESENCHYMAL STROMA CELL; METABOLISM; PROCEDURES;

MURINAE; MUS;

ANIMALS; CELLS, CULTURED; CHEMOKINE CXCL12; COLLAGEN TYPE VII; EPIDERMOLYSIS BULLOSA DYSTROPHICA; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 84927950064     PISSN: None     EISSN: 17576512     Source Type: Journal    
DOI: 10.1186/scrt511     Document Type: Article

References (63)

1. Fine JD, Bruckner-Tuderman L, Eady RA, Bauer EA, Bauer JW, Has C, Heagerty A, Hintner H, Hovnanian A, Jonkman MF, Leigh I, Marinkovich MP, Martinez AE, McGrath JA, Mellerio JE, Moss C, Murrell DF, Shimizu H, Uitto J, Woodley D, Zambruno G: Inherited epidermolysis bullosa: updated recommendations on diagnosis and classification. J AmAcad Dermatol 2014, 70:1103-1126.
2. Shimizu H, McGrath JA, Christiano AM, Nishikawa T, Uitto J: Molecular basis of recessive dystrophic epidermolysis bullosa: genotype/phenotype correlation in a case of moderate clinical severity. J Invest Dermatol 1996, 106:119-124.
3. Dang N, Murrell DF: Mutation analysis and characterization of COL7A1 mutations in dystrophic epidermolysis bullosa. Exp Dermatol 2008, 17:553-568.
4. McGrath JA, Ishida-Yamamoto A, O'Grady A, Leigh IM, Eady RA: Structural variations in anchoring fibrils in dystrophic epidermolysis bullosa: correlation with type VII collagen expression. J Invest Dermatol 1993, 100:366-372.
5. Woodley DT, Hou Y, Martin S, Li W, Chen M: Characterization of molecular mechanisms underlying mutations in dystrophic epidermolysis bullosa using site-directed mutagenesis. J Biol Chem 2008, 283:17838-17845.
6. Ortiz-Urda S, Thyagarajan B, Keene DR, Lin Q, Fang M, Calos MP, Khavari PA: Stable nonviral genetic correction of inherited human skin disease. Nat Med 2002, 8:1166-1170.
7. Woodley DT, Remington J, Huang Y, Hou Y, Li W, Keene DR, ChenM: Intravenously injected human fibroblasts home to skin wounds, deliver type VII collagen, and promote wound healing. Mol Ther 2007, 15:628-635.
8. Osborn MJ, Starker CG, McElroy AN, Webber BR, Riddle MJ, Xia L, DeFeo AP, Gabriel R, Schmidt M, von Kalle C, Carlson DF, Maeder ML, Joung JK, Wagner JE, Voytas DF, Blazar BR, Tolar J: TALEN-based gene correction for epidermolysis bullosa. Mol Ther 2013, 21:1151-1159.
9. Cutlar L, Greiser U, Wang W: Gene therapy: pursuing restoration of dermal adhesion in recessive dystrophic epidermolysis bullosa. Exp Dermatol 2014, 23:1-6.
10. Petrof G, Martinez-Queipo M, Mellerio JE, Kemp P, McGrath JA: Fibroblast cell therapy enhances initial healing in recessive dystrophic epidermolysis bullosa wounds: results of a randomized, vehicle-controlled trial. Br J Dermatol 2013, 169:1025-1033.
11. Venugopal SS, Yan W, Frew JW, Cohn HI, Rhodes LM, Tran K, Melbourne W, Nelson JA, Sturm M, Fogarty J, Marinkovich MP, Igawa S, Ishida-Yamamoto A, Murrell DF: A phase II randomized vehicle-controlled trial of intradermal allogeneic fibroblasts for recessive dystrophic epidermolysis bullosa. J Am Acad Dermatol 2013, 69:898-908.e7.
12. Woodley DT, Keene DR, Atha T, Huang Y, Lipman K, Li W, Chen M: Injection of recombinant human type VII collagen restores collagen function in dystrophic epidermolysis bullosa. Nat Med 2004, 10:693-695.
13. Remington J, Wang X, Hou Y, Zhou H, Burnett J, Muirhead T, Uitto J, Keene DR, Woodley DT, Chen M: Injection of recombinant human type VII collagen corrects the disease phenotype in a murine model of dystrophic epidermolysis bullosa. Mol Ther 2009, 17:26-33.
14. Woodley DT, Wang X, Amir M, Hwang B, Remington J, Hou Y, Uitto J, Keene D, Chen M: Intravenously injected recombinant human type VII collagen homes to skin wounds and restores skin integrity of dystrophic epidermolysis bullosa. J Invest Dermatol 2013, 133:1910-1913.
15. Wagner JE, Ishida-Yamamoto A, McGrath JA, Hordinsky M, Keene DR, Woodley DT, Chen M, Riddle MJ, Osborn MJ, Lund T, Dolan M, Blazar BR, Tolar J: Bone marrow transplantation for recessive dystrophic epidermolysis bullosa. N Engl J Med 2010, 363:629-639.
16. Tolar J, Wagner JE: Management of severe epidermolysis bullosa by haematopoietic transplant: principles, perspectives and pitfalls. Exp Dermatol 2012, 21:896-900.
17. Tolar J, Blazar BR, Wagner JE: Concise review: Transplantation of human hematopoietic cells for extracellular matrix protein deficiency in epidermolysis bullosa. Stem Cells 2011, 29:900-906.
18. Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P, Grisanti S, Gianni AM: Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002, 99:3838-3843.
19. Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, Patil S, Hardy W, Devine S, Ucker D, Deans R, Moseley A, Hoffman R: Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 2002, 30:42-48.
20. Wang JF, Wang LJ, Wu YF, Xiang Y, Xie CG, Jia BB, Harrington J, McNiece IK: Mesenchymal stem/progenitor cells in human umbilical cord blood as support for ex vivo expansion of CD34(+) hematopoietic stem cells and for chondrogenic differentiation. Haematologica 2004, 89:837-844.
21. Tolar J, Hippen KL, Blazar BR: Immune regulatory cells in umbilical cord blood: T regulatory cells and mesenchymal stromal cells. Br J Haematol 2009, 147:200-206.
22. Caplan AI: Why are MSCs therapeutic? New data: new insight. J Pathol 2009, 217:318-324.
23. Lazarus HM, Koc ON, Devine SM, Curtin P, Maziarz RT, Holland HK, Shpall EJ, McCarthy P, Atkinson K, Cooper BW, Gerson SL, Laughlin MJ, Loberiza FR Jr, Moseley AB, Bacigalupo A: Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant 2005, 11:389-398.
24. Koc ON, Gerson SL, Cooper BW, Dyhouse SM, Haynesworth SE, Caplan AI, Lazarus HM: Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J Clin Oncol 2000, 18:307-316.
25. Horwitz EM, Prockop DJ, Fitzpatrick LA, Koo WW, Gordon PL, Neel M, Sussman M, Orchard P, Marx JC, Pyeritz RE, Brenner MK: Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med 1999, 5:309-313.
26. Alexeev V, Uitto J, Igoucheva O: Gene expression signatures of mouse bone marrow-derived mesenchymal stem cells in the cutaneous environment and therapeutic implications for blistering skin disorder. Cytotherapy 2011, 13:30-45.
27. Tolar J, Ishida-Yamamoto A, Riddle M, McElmurry RT, Osborn M, Xia L, Lund T, Slattery C, Uitto J, Christiano AM, Wagner JE, Blazar BR: Amelioration of epidermolysis bullosa by transfer of wild-type bone marrow cells. Blood 2009, 113:1167-1174.
28. Jaerve A, Schira J, Muller HW: Concise review: the potential of stromal cell-derived factor 1 and its receptors to promote stem cell functions in spinal cord repair. Stem Cells Transl Med 2012, 1:732-739.
29. Abbott JD, Huang Y, Liu D, Hickey R, Krause DS, Giordano FJ: Stromal cell-derived factor-1alpha plays a critical role in stem cell recruitment to the heart after myocardial infarction but is not sufficient to induce homing in the absence of injury. Circulation 2004, 110:3300-3305.
30. Jones GN, Moschidou D, Lay K, Abdulrazzak H, Vanleene M, Shefelbine SJ, Polak J, de Coppi P, Fisk NM, Guillot PV: Upregulating CXCR4 in human fetal mesenchymal stem cells enhances engraftment and bone mechanics in a mouse model of osteogenesis imperfecta. Stem Cells Transl Med 2012, 1:70-78.
31. Qi Y, Jiang D, Sindrilaru A, Stegemann A, Schatz S, Treiber N, Rojewski M, Schrezenmeier H, Vander Beken S, Wlaschek M, Bohm M, Seitz A, Scholz N, Durselen L, Brinckmann J, Ignatius A, Scharffetter-Kochanek K: TSG-6 released from intradermally injected mesenchymal stem cells accelerates wound healing and reduces tissue fibrosis in murine full-thickness skin wounds. J Invest Dermatol 2014, 134:526-537.
32. Lee RH, Pulin AA, Seo MJ, Kota DJ, Ylostalo J, Larson BL, Semprun-Prieto L, Delafontaine P, Prockop DJ: Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell 2009, 5:54-63.
33. Chen YQ, Mauviel A, Ryynanen J, Sollberg S, Uitto J: Type VII collagen gene expression by human skin fibroblasts and keratinocytes in culture: influence of donor age and cytokine responses. J Invest Dermatol 1994, 102:205-209.
34. Mauviel A, Lapiere JC, Halcin C, Evans CH, Uitto J: Differential cytokine regulation of type I and type VII collagen gene expression in cultured human dermal fibroblasts. J Biol Chem 1994, 269:25-28.
35. Takeda H, Kon A, Ito N, Sawamura D, Takagaki K, Hashimoto I, Hanada K: Keratinocyte-specific modulation of type VII collagen gene expression by pro-inflammatory cytokines (tumor necrosis factor-alpha and interleukin- 1beta). Exp Dermatol 2005, 14:289-294.
36. Naso M, Uitto J, Klement JF: Transcriptional control of the mouse Col7a1 gene in keratinocytes: basal and transforming growth factor-beta regulated expression. J Invest Dermatol 2003, 121:1469-1478.
37. Calonge MJ, Seoane J, Massague J: Opposite Smad and chicken ovalbumin upstream promoter transcription factor inputs in the regulation of the collagen VII gene promoter by transforming growth factor-beta. J Biol Chem 2004, 279:23759-23765.
38. Knaup J, Gruber C, Krammer B, Ziegler V, Bauer J, Verwanger T: TGFbeta-signaling in squamous cell carcinoma occurring in recessive dystrophic epidermolysis bullosa. Anal Cell Pathol (Amst) 2011, 34:339-353.
39. Zhu H, Guo ZK, Jiang XX, Li H, Wang XY, Yao HY, Zhang Y, Mao N: A protocol for isolation and culture of mesenchymal stem cells from mouse compact bone. Nat Protoc 2010, 5:550-560.
40. Potapova IA, Brink PR, Cohen IS, Doronin SV: Culturing of human mesenchymal stem cells as three-dimensional aggregates induces functional expression of CXCR4 that regulates adhesion to endothelial cells. J Biol Chem 2008, 283:13100-13107.
41. Fritsch A, Loeckermann S, Kern JS, Braun A, Bosl MR, Bley TA, Schumann H, von Elverfeldt D, Paul D, Erlacher M, Berens von Rautenfeld D, Hausser I, Fassler R, Bruckner-Tuderman L: A hypomorphic mouse model of dystrophic epidermolysis bullosa reveals mechanisms of disease and response to fibroblast therapy. J Clin Invest 2008, 118:1669-1679.
42. Alexeev V, Donahue A, Uitto J, Igoucheva O: Analysis of chemotactic molecules in bone marrow-derived mesenchymal stem cells and the skin: Ccl27-Ccr10 axis as a basis for targeting to cutaneous tissues. Cytotherapy 2013, 15:171-184.e1.
43. Lin Q, Wesson RN, Maeda H, Wang Y, Cui Z, Liu JO, Cameron AM, Gao B, Montgomery RA, Williams GM, Sun Z: Pharmacological mobilization of endogenous stem cells significantly promotes skin regeneration after full-thickness excision: the synergistic activity of AMD3100 and tacrolimus. J Invest Dermatol 2014, 134:2458-2468.
44. Wang D, Park JS, Chu JS, Krakowski A, Luo K, Chen DJ, Li S: Proteomic profiling of bone marrow mesenchymal stem cells upon transforming growth factor beta1 stimulation. J Biol Chem 2004, 279:43725-43734.
45. Spector M: Musculoskeletal connective tissue cells with muscle: expression of muscle actin in and contraction of fibroblasts, chondrocytes, and osteoblasts. Wound Repair Regen 2001, 9:11-18.
46. Faryniarz DA, Chaponnier C, Gabbiani G, Yannas IV, Spector M: Myofibroblasts in the healing lapine medial collateral ligament: possible mechanisms of contraction. J Orthop Res 1996, 14:228-237.
47. Behfar A, Yamada S, Crespo-Diaz R, Nesbitt JJ, Rowe LA, Perez-Terzic C, Gaussin V, Homsy C, Bartunek J, Terzic A: Guided cardiopoiesis enhances therapeutic benefit of bone marrow human mesenchymal stem cells in chronic myocardial infarction. J Am Coll Cardiol 2010, 56:721-734.
48. Tu B, Peng ZX, Fan QM, Du L, Yan W, Tang TT: Osteosarcoma cells promote the production of pro-tumor cytokines in mesenchymal stem cells by inhibiting their osteogenic differentiation through the TGF-beta/ Smad2/3 pathway. Exp Cell Res 2014, 320:164-173.
49. Spaeth EL, Dembinski JL, Sasser AK, Watson K, Klopp A, Hall B, Andreeff M, Marini F: Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS One 2009, 4:e4992.
50. Al-toub M, Almusa A, Almajed M, Al-Nbaheen M, Kassem M, Aldahmash A, Alajez NM: Pleiotropic effects of cancer cells' secreted factors on human stromal (mesenchymal) stem cells. Stem Cell Res Ther 2013, 4:114.
51. Bierie B, Moses HL: Transforming growth factor beta (TGF-beta) and inflammation in cancer. Cytokine Growth Factor Rev 2010, 21: 49-59.
52. Weeks BH, He W, Olson KL, Wang XJ: Inducible expression of transforming growth factor beta1 in papillomas causes rapid metastasis. Cancer Res 2001, 61:7435-7443.
53. Li Q, Wang Y, Deng Z: Pre-conditioned mesenchymal stem cells: a better way for cell-based therapy. Stem Cell Res Ther 2013, 4:63.
54. Yu SP, Wei Z, Wei L: Preconditioning strategy in stem cell transplantation therapy. Transl Stroke Res 2013, 4:76-88.
55. Hu X, Yu SP, Fraser JL, Lu Z, Ogle ME, Wang JA, Wei L: Transplantation of hypoxia-preconditioned mesenchymal stem cells improves infarcted heart function via enhanced survival of implanted cells and angiogenesis. J Thorac Cardiovasc Surg 2008, 135:799-808.
56. Boopathy AV, Pendergrass KD, Che PL, Yoon YS, Davis ME: Oxidative stress-induced Notch1 signaling promotes cardiogenic gene expression in mesenchymal stem cells. Stem Cell Res Ther 2013, 4:43.
57. Herrmann JL, Wang Y, Abarbanell AM, Weil BR, Tan J, Meldrum DR: Preconditioning mesenchymal stem cells with transforming growth factor-alpha improves mesenchymal stem cell-mediated cardioprotection. Shock 2010, 33:24-30.
58. Tamai K, Yamazaki T, Chino T, Ishii M, Otsuru S, Kikuchi Y, Iinuma S, Saga K, Nimura K, Shimbo T, Umegaki N, Katayama I, Miyazaki J, Takeda J, McGrath JA, Uitto J, Kaneda Y: PDGFRalpha-positive cells in bone marrow are mobilized by high mobility group box 1 (HMGB1) to regenerate injured epithelia. Proc Natl Acad Sci U S A 2011, 108:6609-6614.
59. Ikebe C, Suzuki K: Mesenchymal stem cells for regenerative therapy: optimization of cell preparation protocols. Biomed Res Int 2014, 2014:951512.
60. Wong T, Gammon L, Liu L, Mellerio JE, Dopping-Hepenstal PJ, Pacy J, Elia G, Jeffery R, Leigh IM, Navsaria H, McGrath JA: Potential of fibroblast cell therapy for recessive dystrophic epidermolysis bullosa. J Invest Dermatol 2008, 128:2179-2189.
61. Uitto J: Cell-based therapy for RDEB: how does it work? J Invest Dermatol 2011, 131:1597-1599.
62. Nystrom A, Bruckner-Tuderman L, Kern JS: Cell- and protein-based therapy approaches for epidermolysis bullosa. Methods Mol Biol 2013, 961:425-440.
63. Woodley DT, Cogan J, Wang X, Hou Y, Haghighian C, Kudo G, Keene DR, Chen M: De novo anti-type VII collagen antibodies in patients with recessive dystrophic epidermolysis bullosa. J Invest Dermatol 2014, 134:1138-1140.